Nilutamide: Possible utility as a second-line hormonal agent

Urology

Volumn 58, Issue 6, 2001, Pages 1016-1020

  Desai, Apurva ^a   Stadler, Walter M ^a   Vogelzang, Nicholas J ^b,c  

^a UNIVERSITY OF CHICAGO   (United States)

^b University of Chicago   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; BICALUTAMIDE; DOXORUBICIN; FLUTAMIDE; GOSERELIN; KETOCONAZOLE; LEUPRORELIN; MITOXANTRONE; NILUTAMIDE; PACLITAXEL; PC SPES; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR; SURAMIN;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DARK ADAPTATION; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HOT FLUSH; HUMAN; LIGHT ADAPTATION; MALE; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CARCINOMA;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; HUMANS; IMIDAZOLES; IMIDAZOLIDINES; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 0035661103     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(01)01455-8     Document Type: Article

References (24)

1. Cancer statistics, 2000
2. Maximum androgen blockade in advanced prostate cancer: An overview of the randomized trials
3. Second-line hormonal therapy for advanced prostate cancer: A shifting paradigm
4. Natural history of progression after PSA elevation following radical prostatectomy
5. Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer: Analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer - Genitourinary Group Study 30853
6. Prostate specific antigen decline after anti-androgen withdrawal: The flutamide withdrawal syndrome
7. Prostate specific antigen decreases after withdrawal of anti-androgen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade
8. Bicalutamide for advanced prostate cancer: The natural versus treated history of disease
9. Eligibility and response guidelines for phase II clinical trials in androgen independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group
10. Nilutamide: An anti-androgen for the treatment of prostate cancer
11. Studies on prostatic carcinoma. II. The effects of castration on advanced carcinoma of the prostate gland
12. Secondary hormonal manipulations in hormone refractory prostate cancer
13. High dose bicalutamide for androgen independent prostate cancer: Effect of prior hormonal therapy
14. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer
15. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence
16. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer
17. The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate
18. Nilutamide response after flutamide failure in post orchiectomy progressive prostate cancer
19. A prognostic score for hormone refractory prostate cancer: Analysis of two Cancer and Leukemia Group B studies
20. Anti-androgen withdrawal syndrome with nilutamide
21. Are non-steroidal anti-androgens appropriate as monotherapy in advanced prostate cancer?
22. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer
23. High-dose ketoconazole in advanced hormone-refractory prostate cancer: Endocrinologic and clinical effects
24. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal